
think fundament like improv complex
gener product gain approv believ multipl
shot deliv upsid surpris gener pipelin
includ advair restasi lantu base increas
confid co abil deliv gener pipelin
increas ep estim
current consensu ep estim estim co
gener total revenu adj ebitda adj
free cash flow believ result benefit
launch gener copaxon approv last octob
partner natco first co gain approv mg strength
expect american segment benefit
mylan valuat remain discount share trade
ep estim ev ebitda multipl
base estim estim trade
 discount specialti pharma peer group
global pharma co diversifi revenu base
 america europ row vertic
integr suppli chain view one co
global scale scope one-stop shop gener
potenti biocon momenta partnership believ
current develop biosimilar product
opportun includ top best-sel biolog product
think biosimilar version herceptin brand us
opportun could launch time-frame
expect benefit launch gener copaxon base
symphoni health prescript data gener mg
copaxon share new share total
prescript ep estim
consensu ep forecast
valuat maintain buy rate share
increas pt page detail
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
up estim reflect potenti addit complex gener launch
think fundament like improv complex gener product gain approv
believ multipl product opportun could receiv approv lead upsid surpris
 gener pipelin includ advair restasi lantu base increas
confid co abil deliv gener pipelin increas ep estim
current consensu ep estim estim co
gener total revenu adj ebitda adj free cash flow
believ result benefit launch gener copaxon approv last octob
partner natco nctph rate first co gain approv mg strength expect
american segment benefit
global pharma co diversifi revenu base america europ
row vertic integr suppli chain view one co global
scale scope one-stop shop gener rx product addit vertic integr capabl
think co intern access raw materi low cost manufactur india
mylan manufactur site across globe
believ myl valuat remain discount share trade ep estim
ev ebitda multipl base estim estim trade
discount specialti pharma peer group view visibl co gener biosimilar pipelin
like improv look toward middl year would expect potenti
posit one first co receiv fda approv gener advair co plan
commerci tradenam wixela inhub dedic manufactur facil dublin ireland
complet end believ facil provid end end drug formul fill
devic assembl capabl provid co abil mass produc product accord
symphoni health excess advair prescript dispens month
mylan gener advair approv launch expect
believ advair fluticasone/salmeterol treatment asthma/copd brand market opportun
us remain key gener product opportun gsk gsk rate advair still one largest
sell brand inhal product us us sale assum two anda
approv price drop think first gener co enter could gener signific
sale market format sale excess within first month launch
recent approv launch gener copaxon increas visibl us
estim copaxon sale book base analysi symphoni health
prescript data gener mg copaxon share new share total prescript
first gener co receiv approv back octob mg believ
co could gener sale gener copaxon within first month adj
ep estim consensu ep forecast
 gener prescript per month advair diskusyoy gener copaxon share market share copaxon tevamarket share copaxon
biosimilar pipelin opportun provid long-term upsid potenti
partnership biocon momenta
believ current develop biosimilar product opportun includ
top best-sel biolog product late last year co receiv fda approv biosimilar version
herceptin trastuzumab brand market opportun us think could launch
 time-frame addit partner momenta rate announc would
look develop biosimilar eylea vegf inhibitor age-rel macular degener diabet
macular edema gener annual sale excess regeneron buy pt analyst dane
ecast ep high end co ep guidanc
rang
earn report last novemb increas bottom end revenu adj ep
guidanc target up revenu rang
adj ep rang reiter target adj free
cash flow cap ex target set also reiter
long-term target reduc debt leverag get debt ebitda estim total revenu
upper end co guidanc rang
valuat analysi increas pt
think fundament like improv complex gener product gain approv
believ multipl product opportun could receiv approv lead upsid surpris
 gener pipelin includ restasi lantu base increas confid
co abil deliv gener pipelin increas ep estim
current consensu ep estim arriv pt share
appli termin multipl ebitda estim discount back
discount analysi suggest share worth
 discount free cash discount discount valu multipl termin termin valu valu per compani report btig estim
 incom statement financi project cost sg oper profit purchas account amort ad interest expens cash expens ep ep averag basic averag dilut compani report btig
btig cover compani mention report
appendix analyst certif import disclosur
